13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001843547
Total reported value
$19.7M
$19.7M
3 檔
29.1%
As reported in its official Q2 2025 Form 13F filing, Vantage Consulting Group Inc's tracked investment portfolio stood at $19.7M with 3 total positions.
During Q2 2025, Vantage Consulting Group Inc's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BW | Babcock & Wilcox Enterpr | Stock-Other | 40.54% | +15.20% | — | |
| 2 | ✓ | Adc Therapeutics SA | Stock-Other | 31.92% | -12.13% | -19.72% | |
| 3 | CBUS | Cibus Inc | Stock-Other | 27.53% | -3.07% | — |
According to official SEC Form 13F filings, Vantage Consulting Group Inc reported a total U.S. public equity portfolio value of $19.7M across 3 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including BW, ADC THERAPEUTICS SA, CBUS) accounted for 29.1% of total reported equity market value during Q2 2025.
During Q2 2025, Vantage Consulting Group Inc's top holdings by market value included BW (40.5%)、ADC THERAPEUTICS SA (31.9%)、CBUS (27.5%). The largest single position, BW, represented 40.5% of total portfolio value.
In Q2 2025, Vantage Consulting Group Inc made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.